Clinical Trials Logo

Filter by:
NCT ID: NCT05627024 Recruiting - Atelectasis Clinical Trials

Effects of Different Inhalation Oxygen Concentrations on Postoperative Atelectasis

DIOCA
Start date: January 11, 2023
Phase: Phase 4
Study type: Interventional

This study was a single-center, prospective, randomized controlled, two-arm study. This study will be conducted in the First Hospital of China Medical University. the investigators aimed to investigate the effects of different inspired oxygen concentrations in lung protective ventilation strategies on immediate postoperative atelectasis and intraoperative changes of oxygenation index in patients undergoing neurosurgical surgery in the supine position.

NCT ID: NCT05626985 Recruiting - Clinical trials for Hepatocellular Carcinoma

Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma

Start date: October 19, 2022
Phase:
Study type: Observational

Most hepatocellular carcinoma (HCC) cases were at advanced stage when diagnosis established. This study is intended to establish a clinical diagnostic model GAMAD for early-stage HCC and evaluate the diagnostic efficiency the same time. This study is a multicenter prospective study. Participants including healthy control,HCC, liver cirrhosis, hepatitis and benign tumor-like lesions are consecutively recruited into the cohort. All the blood samples are collected before any treatments and will be tested in single center in order to decrease bias.

NCT ID: NCT05626829 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Start date: July 20, 2022
Phase: Phase 2
Study type: Interventional

Nasopharyngeal carcinoma is one of the high incidence head and neck cancer in Southeast Asia. Radiotherapy is the main treatment for nasopharyngeal carcinoma, and its response rate can reach 80~90%. However, for radiotherapy resistant patients with metastasis and recurrence, the survival prognosis decreased significantly, and the 5-year overall survival rate was only 20% - 40%. Tranilast is an anti-allergic drug, which is clinically used to treat bronchial asthma and can inhibit fibroblasts α- SMA and type I collagen expression. Through experiments in vivo and in vitro, the investigators' research group has proved that Tranilast can inhibit the activity of tumor related fibroblasts, reduce the radiotherapy resistance of nasopharyngeal carcinoma, and has the radiosensitizing effect of nasopharyngeal carcinoma. This result has been published in J exp Clin cancer res (if=11.16). The investigators plan to carry out the clinical transformation of basic research, carry out a prospective intervention phase II clinical trial, compare the objective remission rate of patients with recurrent nasopharyngeal carcinoma treated with previous radiotherapy, and explore the safety and effectiveness of using Tranilast as a radiotherapy sensitizer for radiotherapy to resist the treatment of nasopharyngeal carcinoma.

NCT ID: NCT05626569 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Start date: December 10, 2022
Phase: Phase 2
Study type: Interventional

The goal of this phase II clinical trial is to explore the efficacy and safety of anti-PD1 combined with stereotactic body radiation therapy (SBRT) for patients with oligometastatic esophageal squamous cell carcinoma. Participants will receive anti-PD1 and SBRT to the metastatic lesions which are amenable to the delivery of SBRT after 4~6 cycles of systemic chemotherapy and anti-PD-1.

NCT ID: NCT05626400 Recruiting - Clinical trials for T-cell Acute Lymphoblastic Leukemia/Lymphoma

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Start date: August 29, 2022
Phase: N/A
Study type: Interventional

This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD indexes of Senl-T7 were collected.

NCT ID: NCT05626348 Recruiting - Clinical trials for Arthritis, Rheumatoid

The Clinical Efficacy of Immunomodulators in RA Patients

Start date: December 22, 2021
Phase: Phase 4
Study type: Interventional

This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.

NCT ID: NCT05626309 Recruiting - Esophagus Cancer Clinical Trials

Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Qizhu Yuling prescription for postoperative esophagus cancer.

NCT ID: NCT05626296 Recruiting - Clinical trials for Ischemic Stroke, Acute

Molecular Network Characteristics of Phlegm-heat Syndrome in Ischemic Stroke Based on Multi-omics Integrated Analysis

Start date: November 14, 2022
Phase:
Study type: Observational

The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.

NCT ID: NCT05626179 Completed - Healthy Subjects Clinical Trials

A Study of [14C]IBI351 in Healthy Subjects

Start date: February 18, 2023
Phase: Phase 1
Study type: Interventional

This study is to evaluate the mass balance of single oral dose of [14C] IBI351 in healthy subjects. Six to eight healthy male subjects were planned to be enrolled. After passing the screening, subjects were admitted to hospital and received training on medication, urine and feces collection and other procedures to ensure that they could perform relevant operations according to the protocol and SOP requirements. On the evening before medication, the patient had standard meals, and fasted uniformly overnight. On D1, the suspension containing recommended dose of [14C] IBI351 was administered in the morning on an empty stomach. Subjects have standardized meal during the trial and blood, urine, and feces samples were collected and safety laboratory tests were performed as scheduled.

NCT ID: NCT05626153 Not yet recruiting - Anesthesia Clinical Trials

Anesthesia Quality Improvement and Patients With Planned ICU Admission

Start date: December 2022
Phase: N/A
Study type: Interventional

Intensive care unit (ICU) is an important part of perioperative management for high-risk patients but is associated with higher medical costs. Improper ICU admission may produce overtreatment without beneficial effects. In clinical practice, delayed recovery after general anesthesia is a common indication for ICU admission after surgery. The concept of Enhanced Recovery After Surgery recommends early extubation. The investigators suppose that, for patients with planned ICU admission after elective surgery, implementing anesthesia quality improvement including extubation in the operating room will reduce the rate of ICU admission after surgery without increasing complications.